Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

Overview of attention for article published in Clinical and Translational Oncology, November 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 48 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer : Committee papers

Cited by National Institute for Health and Care Excellence on 21 Nov 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.